GSK's Relief For Few Months, First Trial Claiming Zantac Caused Cancer Pushed Into Late 2023
The first scheduled trial expected next week, related to GSK Plc's (NYSE: GSK) Zantac associated with cancer, has been postponed, likely by several months.
The case is expected to go to trial in June or July, though no date has yet been set, Reuters Reported.
The case brought by California resident James Goetz in Alameda County Superior Court alleges that he developed bladder cancer from taking Zantac. His case will offer an early test of how Zantac cancer claims may fare in state courts.
U.S. District Judge Robin Rosenberg in Florida dismissed about 50,000 claims related to the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by solid science.
In August last year, the plaintiff dismissed GSK's first scheduled Zantac related-cancer trial out of 3,000, noting that it did not settle the claim and has not paid anything in exchange for the voluntary dismissal.
Tens of thousands of cases remain in state courts. Many consolidated before Judge Evelio Grillo in Alameda.
In 2019, the FDA noted that Zantac produces unacceptably high levels of a cancer-causing chemical when exposed to heat for as little as five days. The product was removed from the market in 2020.
Price Action: GSK shares are down 1.87% at $34.60 on the last check Friday.
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article GSK's Relief For Few Months, First Trial Claiming Zantac Caused Cancer Pushed Into Late 2023 originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
